Exactech, Inc. (NASDAQ:EXAC) updated its FY17 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.27-1.31 for the period, compared to the Thomson Reuters consensus estimate of $1.30. The company issued revenue guidance of $267-271 million, compared to the consensus revenue estimate of $270.33 million.Exactech also updated its Q3 guidance to $0.23-0.25 EPS.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Exactech from a sell rating to a hold rating in a report on Monday, May 1st. TheStreet raised Exactech from a c+ rating to a b rating in a report on Tuesday, April 25th.

Exactech, Inc. (EXAC) remained flat at $30.50 during trading on Thursday. 27,975 shares of the company traded hands. Exactech, Inc. has a 1-year low of $22.20 and a 1-year high of $31.90. The firm has a 50 day moving average price of $30.29 and a 200-day moving average price of $27.86. The company has a market capitalization of $436.52 million, a P/E ratio of 1270.83 and a beta of 1.03.

Exactech (NASDAQ:EXAC) last posted its quarterly earnings results on Tuesday, April 25th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.03. Exactech had a net margin of 0.13% and a return on equity of 7.27%. The firm had revenue of $69.48 million during the quarter, compared to analyst estimates of $67.05 million. During the same quarter in the prior year, the business posted $0.31 earnings per share. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities research analysts predict that Exactech, Inc. will post $1.30 EPS for the current fiscal year.

In other news, CFO Joel C. Phillips sold 7,610 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $30.71, for a total transaction of $233,703.10. Following the completion of the sale, the chief financial officer now owns 99,907 shares of the company’s stock, valued at $3,068,143.97. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William B. Locander sold 988 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $30.34, for a total transaction of $29,975.92. Following the sale, the director now directly owns 8,555 shares of the company’s stock, valued at approximately $259,558.70. The disclosure for this sale can be found here. Corporate insiders own 28.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/27/exactech-inc-nasdaqexac-releases-fy17-earnings-guidance.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Earnings History and Estimates for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.